Condition (MeSH)
Hearing Loss, Sudden
ClinicalTrials.gov lists 63 trials for Hearing Loss, Sudden or a narrower condition beneath it. Frequency Therapeutics has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
63 of the 63 trials are tagged with Hearing Loss, Sudden itself; the rest are tagged with a narrower condition beneath it.
When did Hearing Loss, Sudden trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 6 |
| 2024 | 7 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 6 |
| 2020 | 9 |
| 2019 | 5 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 17 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 9 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 32 months across 23 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hearing Loss, Sudden trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 6 |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 5 |
| Phase 4 | 4 |
| Not applicable | 15 |
| Observational | 14 |
How many Hearing Loss, Sudden trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 13 |
| Recruiting | 7 |
| Enrolling by invitation | 2 |
| Completed | 19 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hearing Loss, Sudden trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Frequency Therapeutics | 4 |
| Tel-Aviv Sourasky Medical Center | 3 |
| Auris Medical AG | 1 |
Which drugs are being tested for Hearing Loss, Sudden? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| METHYLPREDNISOLONE | 6 |
| Prednisone | 3 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dexamethasone/Dexamethasone acetate | 6 |
| FX-322 | 4 |
| Hyaluronic acid 1% | 3 |
| Acupuncture | 2 |
| Anakinra alone (stages 2b/3) | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hearing Loss, Sudden trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| myocardial infarction | 2 | 1 |
| Bladder cancer | 1 | 1 |
| COPD exacerbation | 1 | 1 |
| Cerebral hemorrhage | 1 | 1 |
| Device-related infection | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hearing Loss, Sudden? (48)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Adverse Effects of Steroid Therapy in Sudden Sensorineural Hearing Loss: A Scoping Review. | Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery | 2025 | Yes |
| The relationship between serum homocysteine levels and sudden sensorineural hearing loss: a meta-analysis. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2023 | Yes |
| Prognosis of vestibular dysfunction in idiopathic sudden sensorineural hearing loss with vertigo: a prospective cohort study. | Journal of neurology | 2023 | Yes |
| Prognostic Value of Early Magnetic Resonance Imaging Patterns in Sudden Hearing Loss. | Audiology & neuro-otology | 2022 | Yes |
| International Multicenter Registry for Hyperbaric Oxygen Therapy: Results through June 2021. | Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc | 2022 | Yes |
Showing 5 of 48 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Sudden sensorineural hearing loss | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.